While malignancy may be the most feared adverse event of anti-TNF therapy, real world experience shows patients are up to 50 times more likely to develop a serious infection than cancer. A French study of almost 200,000 patients with IBD treated with anti-TNFs and/or thiopurines has shown the annual incidence of serious infections requiring hospitalisation ...
Infection risks with anti-TNFs highlight need for vaccinations
By Michael Woodhead
12 Jul 2018